Lite Strategy Inc (LITS)
NASDAQ:LITS
Voruciclib Monotherapy, Voruciclib And Venetoclax
Follicular Lymphoma (Fl), Small Lymphocytic Lymphoma (Sll), Marginal Zone Lymphoma (Mzl), Chronic Lymphocytic Leukemia (Cll), Acute Myeloid Leukemia (Aml), Mantle Cell Lymphoma (Mcl), Diffuse Large B-Cell Lymphoma (Dlbcl)
Phase I
Terminated
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
May 24, 2018
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Lite Strategy Inc (LITS) have in its pipeline
LITS is currently developing the following drugs: Voruciclib Monotherapy, Voruciclib And Venetoclax. These drug candidates are in various stages of clinical development as the company works toward FDA approval.